Human iPSC-derived Parkinson's disease model (SNCA mutation) in commercially available excitatory neurons
Glutamatergic Neurons SNCA A53T/WT express neuron-specific markers ICC staining
SNCA-mutated glutamatergic neurons mature rapidly and form structural neuronal networks
Gene expression analysis (RT-qPCR) in human iPSC-derived Glutamatergic Neurons SNCA A53T/WT
One small vial seeds 1 x 96-well plate or 1.5 x 384-well plates.
Human iPSC-derived Parkinson's disease model (SNCA mutation) in commercially available excitatory neurons
Glutamatergic Neurons SNCA A53T/WT express neuron-specific markers ICC staining
SNCA-mutated glutamatergic neurons mature rapidly and form structural neuronal networks
Gene expression analysis (RT-qPCR) in human iPSC-derived Glutamatergic Neurons SNCA A53T/WT
One small vial seeds 1 x 96-well plate or 1.5 x 384-well plates.

cat no | io6005

ioGlutamatergic Neurons SNCA A53T/WT

Human iPSC-derived Parkinson's disease model

  • Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days

  • In vitro cell model engineered with a mutation in alpha-synuclein for Parkinson's disease research

  • Consistent, functional excitatory neurons that form neuronal networks within days

Place your order

Human iPSC-derived Parkinson's disease model (SNCA mutation) in commercially available excitatory neurons

Human iPSC-derived Parkinson's disease model

Glutamatergic Neurons SNCA A53T/WT express neuron-specific markers ICC staining

ioGlutamatergic Neurons SNCA A53T/WT express neuron-specific markers comparably to the wild type control

Immunofluorescent staining on day 11 post-revival demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 and glutamatergic neuron-specific transporter VGLUT2 in ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) compared to the genetically matched control. 100X magnification.

SNCA-mutated glutamatergic neurons mature rapidly and form structural neuronal networks

ioGlutamatergic Neurons SNCA A53T/WT form structural neuronal networks by day 10

ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) mature rapidly and form structural neuronal networks over 10 days, highly similar to the genetically matched control. Day 1 to 10 post thaw; 100X magnification.

Gene expression analysis (RT-qPCR) in human iPSC-derived Glutamatergic Neurons SNCA A53T/WT

ioGlutamatergic Neurons SNCA A53T/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming

Gene expression analysis demonstrates that ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

One small vial seeds 1 x 96-well plate or 1.5 x 384-well plates.

Industry leading seeding density

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Vial limit exceeded

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.

Human iPSC-derived Parkinson's disease model

ioGlutamatergic Neurons SNCA A53T/WT are opti‑ox deterministically programmed excitatory neurons carrying a genetically engineered heterozygous A53T mutation in the SNCA gene encoding the alpha-synuclein protein. These cells offer a rapidly maturing, consistent and scalable system to study Parkinson's disease (PD).

This disease model is part of a Parkinson's disease panel of physiologically relevant human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. Additional products in the PD panel include homozygous SNCA A53T, PRKN R275W, PINK1 Q456X and GBA mutations. All disease model cells in the PD panel can be used alongside their genetically matched control, ioGlutamatergic Neurons

A second SNCA A53T/WT clone is available on enquiry. Studying multiple clones of a specific disease model can lead to a more comprehensive understanding of the impact of the disease-relevant mutation and cellular heterogeneity on associated disease phenotypes. 

Benchtop benefits

comparison_0

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of the alpha-synuclein mutation on cellular and molecular mechanisms and cell function.

scalable_0

Scalable

With opti-ox technology, we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.

quick_0

Quick

The disease model cells and genetically matched control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 10 days.

Schematic overview of the timeline in the user manual


ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons SNCA A53T/WT are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Product specifications

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male, age 55-60 years old (skin fibroblast),
Genotype APOE 3/4

Vial size

Small: >1 x 10⁶ viable cells, Evaluation pack*: 3 small vials of >1 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm²

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Heterozygous A53T missense mutation in the SNCA gene

Applications

Parkinson's disease research
Drug discovery and development
Disease modelling

Available clones

io6004: SNCA A53T/WT (621P2B8)
io6005: SNCA A53T/WT (621P2D1)

Product use

ioCells are for research use only

* Evaluation packs are intended for first-time users, or for existing users testing a new cell type or derivative. A user can request multiple evaluation packs as long as each one is for a different product, with only one pack allowed per product.

Technical data

Highly characterised and defined

ioGlutamatergic Neurons SNCA A53T/WT express neuron-specific markers comparably to the wild type control

SNCA-A53T-het-io6005-ICC-MAP2-TUBB3-VGLUT2

Immunofluorescent staining on day 11 post-revival demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 and glutamatergic neuron-specific transporter VGLUT2 in ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) compared to the genetically matched control. 100X magnification.

ioGlutamatergic Neurons SNCA A53T/WT form structural neuronal networks by day 10

SNCA-A53T-het-io6005-Morphology

ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) mature rapidly and form structural neuronal networks over 10 days, highly similar to the genetically matched control. Day 1 to 10 post thaw; 100X magnification.

ioGlutamatergic Neurons SNCA A53T/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming

io6005_SNCA_A53T_Het_RT-qPCR

Gene expression analysis demonstrates that ioGlutamatergic Neurons SNCA A53T/WT (clone 621P2D1) and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Industry leading seeding density

One small vial seeds 1 x 96-well plate or 1.5 x 384-well plates.

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

How to culture ioGlutamatergic Neurons

In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.

Product resources

(LinkedValues: [{hs_name=ioGlutamatergic Neurons Wild Type and related disease models | User Manual, hs_id=161968263487, hs_path=glutamatergic-neurons, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=bit-bio ioGlutamatergic Neurons Day 14 Beta III Tubulin staining copy, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/ioGlutamatergic%20Neurons%20in%20Drug%20Discovery/bit-bio%20ioGlutamatergic%20Neurons%20Day%2014%20Beta%20III%20Tubulin%20staining%20copy.jpeg, height=1200}, year={label=2025, value=2025}, summary=<p>DOC-1289 4.0</p> <p>bit.bio</p> <p>2025<br><br></p>, date_published=1707955200000, sort_date=1713225600000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioGlutamatergic Neurons HTT 50CAG/WT, value=ioGlutamatergic Neurons HTT 50CAG/WT}, {label=ioGlutamatergic Neurons TDP-43 M337V Het, value=ioGlutamatergic Neurons TDP-43 M337V Het}, {label=ioGlutamatergic Neurons TDP-43 M337V Hom, value=ioGlutamatergic Neurons TDP-43 M337V Hom}, {label=ioGlutamatergic Neurons MAPT P301S/WT, value=ioGlutamatergic Neurons MAPT P301S/WT}, {label=ioGlutamatergic Neurons MAPT P301S/P301S, value=ioGlutamatergic Neurons MAPT P301S/P301S}, {label=ioGlutamatergic Neurons MAPT N279K/WT, value=ioGlutamatergic Neurons MAPT N279K/WT}, {label=Product information, value=Product information}, {label=User manual, value=user_manual}], media_contact=<p><span>DOC-1289 4.0</span></p> <p><span>bit.bio</span></p> <p><span>2025</span></p>, listing_button_label=Download}, {hs_name=CRISPRa-Ready ioGlutamatergic Neurons | User Manual, hs_id=186090210329, hs_path=crispr-activation-ready-glutamatergic-neurons, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=bit.bio-CRISPRa-ready-ioGlutamatergic-neurons-map2-staining, width=856, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioGlutamatergic%20Neurons/CRISPRa-Ready%20ioGlutamatergic%20Neurons/bit.bio-CRISPRa-ready-ioGlutamatergic-neurons-map2-staining.png, height=856}, year={label=2025, value=2025}, summary=V1<br>2025<br>bit.bio, date_published=1739404800000, sort_date=1739404800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=Product information, value=Product information}, {label=CRISPRa-Ready ioGlutamatergic Neurons, value=crispra-ready_ioglutamatergic_neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=User manual, value=user_manual}], media_contact=V1<br>2025<br>bit.bio, listing_button_label=Download}, {hs_name=CRISPRi-Ready ioGlutamatergic Neurons | User Manual, hs_id=186807423031, hs_path=crispri-ready-ioglutamatergic-neurons-user-manual, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=bit.bio-io1098-CRISPRi-ready-glutamatergic-neurons-tubb3-staining, width=856, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioGlutamatergic%20Neurons/CRISPRi-Ready%20ioGlutamatergic%20Neurons/bit.bio-io1098-CRISPRi-ready-glutamatergic-neurons-tubb3-staining.png, height=796}, year={label=2025, value=2025}, summary=V1<br>2025<br>bit.bio, date_published=1740960000000, sort_date=1740960000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=Product information, value=Product information}, {label=User manual, value=user_manual}], media_contact=V1<br>2025<br>bit.bio, listing_button_label=Download}, {hs_name=Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells, hs_id=161968263519, hs_path=modelling-neurodevelopment-webinar-2022, button_label=Explore ioGlutamatergic Neurons, button_link=https://www.bit.bio/products/nerve-cells/glutamatergic-neurons-wild-type-io1001, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/BitBio2022/product-page/Colour%20webinar%20with%2060x%20Map2-com.jpg, height=732}, year={label=2022, value=2022}, summary=<p><span>Dr Deepak Srivastava | King’s College London<br><br></span><span></span></p>, date_published=1707436800000, sort_date=1649376000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=Webinars , value=webinars}, {label=Webinar | Modelling neurodevelopment , value=webinar_|_modelling_neurodevelopment}, {label=ioGABAergic Neurons!, value=iogabaergic_neurons}], media_contact=null, listing_button_label=Watch now}, {hs_name=Rethinking Developmental Biology With Cellular Reprogramming, hs_id=161968263524, hs_path=rethinking-developmental-biology-with-cellular-reprogramming, button_label=Explore ioCells, button_link=https://www.bit.bio/discover-iocells, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1860, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Upcoming%20Webinars/Tech%20Nets%202023/bit.bio_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png, height=1260}, year={label=2023, value=2023}, summary=<p>Mark Kotter | CEO and founder | bit.bio</p> <p>Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |&nbsp; Stanford University</p>, date_published=1709164800000, sort_date=1681776000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioMicroglia, value=ioMicroglia}, {label=Cell therapy, value=Cell therapy}, {label=ioSensory Neurons, value=ioSensory Neurons}, {label=ioOligodendrocyte-like cells, value=ioOligodendrocyte-like cells}, {label=Webinars , value=webinars}, {label=Webinar | Rethinking Developmental Biology, value=webinar_|_rethinking_developmental_biology}, {label=ioGABAergic Neurons!, value=iogabaergic_neurons}], media_contact=null, listing_button_label=Watch now}, {hs_name=Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming, hs_id=161968263525, hs_path=addressing-the-reproducibility-crisis-driving-genome-wide-consistency-in-cellular-reprogramming, button_label=Explore ioCells, button_link=https://www.bit.bio/discover-iocells, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1860, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Upcoming%20Webinars/Tech%20Nets%2019th%20July%202023/bit.bio_ioGlutamatergic%20Neurons_60xMAP2(red)Hoescht(blue)TUBB3(blue)_day4.jpg, height=1260}, year={label=2023, value=2023}, summary=<p>Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio</p>, date_published=1709769600000, sort_date=1689724800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioSensory Neurons, value=ioSensory Neurons}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=Webinars , value=webinars}, {label=Webinar | Addressing the Reproducibility Crisis, value=webinar Addressing the Reproducibility Crisis}], media_contact=null, listing_button_label=Watch now}, {hs_name=Running Large-Scale CRISPR Screens in Human Neurons, hs_id=161968263528, hs_path=running-large-scale-crispr-screens-in-human-neurons, button_label=null, button_link=null, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Emails/Header%20images/Header%20Images%20-%20ICC%20only/Running%20Large-Scale%20CRISPR%20Screens%20in%20Human%20Neurons_email%20header.png, height=678}, year={label=2023, value=2023}, summary=<p>Emmanouil Metzakopian | Vice President, Research and Development | bit.bio</p> <p>Javier Conde-Vancells | Director Product Management | bit.bio</p>, date_published=1710460800000, sort_date=1700524800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=CRISPR-Ready ioMicroglia, value=CRISPR-Ready ioMicroglia}, {label=Webinars , value=webinars}, {label=Webinar Running Large-Scale CRISPR Screens, value=webinar_running_large-scale_crispr_screens}], media_contact=null, listing_button_label=Watch now}, {hs_name=Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease, hs_id=183096620633, hs_path=human-ipsc-based-models-of-glial-cells-for-studying-neurodegenerative-disease, button_label=null, button_link=null, type={label=Webinar, value=Webinar}, thumbnail={alt_text=bitbio-oligodendrocyte-like-cells-O4-MBP-immunocytochemistry, width=1000, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioOligodendrocyte-like%20cells/bitbio-oligodendrocyte-like-cells-O4-MBP-immunocytochemistry.jpg, height=1350}, year={label=2024, value=2024}, summary=Valentina Fossati, PhD | Senior Research Investigator | The New York Stem Cell Foundation<br><br>Inês Ferreira | Senior Product Manager | bit.bio, date_published=1732233600000, sort_date=1732233600000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioOligodendrocyte-like cells, value=ioOligodendrocyte-like cells}, {label=Webinars , value=webinars}, {label=Webinar | Human iPSC-Based Models of Glial , value=webinar_|_human_ipsc-based_models_of_glial}], media_contact=null, listing_button_label=Watch now}])
CRISPRi-Ready ioGlutamatergic Neurons | User Manual User manual
CRISPRi-Ready ioGlutamatergic Neurons | User Manual
V1
2025
bit.bio
Download
CRISPRa-Ready ioGlutamatergic Neurons | User Manual User manual
CRISPRa-Ready ioGlutamatergic Neurons | User Manual
V1
2025
bit.bio
Download
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease Webinar
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease
Valentina Fossati, PhD | Senior Research Investigator | The New York Stem Cell Foundation

Inês Ferreira | Senior Product Manager | bit.bio
Watch now
ioGlutamatergic Neurons Wild Type and related disease models | User Manual User manual
ioGlutamatergic Neurons Wild Type and related disease models | User Manual

DOC-1289 4.0

bit.bio

2025

Download
Running Large-Scale CRISPR Screens in Human Neurons Webinar
Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming Webinar
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio

Watch now
Rethinking Developmental Biology With Cellular Reprogramming Webinar
Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells Webinar
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells

Dr Deepak Srivastava | King’s College London

Watch now

Cell culture hacks | human iPSC-derived glutamatergic neurons

Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.

bit.bio_Lab_May22_Pic0034

ioCells catalogue

Human iPSC-derived cells

powered by opti-ox

Consistent. Defined. Scalable.

bitbio-cell_catalogue_header-with-tracker-Desktop-2500x1664